ICUI

Business Context and Reporting Period

Company: ICU Medical, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2002
Business Overview: ICU Medical is a leader in developing and manufacturing proprietary, disposable medical connection systems for intravenous (I.V.) therapy, designed to prevent needlestick injuries. The company sells products to medical product manufacturers (primarily Abbott Laboratories and B. Braun Medical Inc.), independent distributors, and international markets.

Key Financial Metrics

Note: All dollar amounts in thousands except per share data. No long-term debt is reported on the balance sheet.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 34% in Q2 2002 and 36% YTD compared to the prior year periods. This was driven by a 39% increase in CLAVE product sales and a 49% increase in custom and generic I.V. systems.
• Customer Concentration: Sales to Abbott Laboratories accounted for 65% of Q2 2002 revenue (up from 43% in Q2 2001). Conversely, sales to B. Braun Medical Inc. dropped significantly to 10% of Q2 revenue (down from 27% in Q2 2001) due to contractual disputes and inventory balancing by the customer.
• Profitability: Net income rose 33% in Q2 and 30% YTD. Gross margins remained stable at 59% despite price reductions, as manufacturing efficiencies and higher volumes offset lower average selling prices.
• Expenses: Selling, General, and Administrative (SG&A) expenses increased 28% in Q2, largely due to legal fees associated with litigation against B. Braun. R&D expenses remained relatively flat.
• Liquidity: Cash and liquid investments increased to $87.7 million as of June 30, 2002, up from $73.0 million at year-end 2001, supported by strong operating cash flows and proceeds from stock option exercises.

Outlook, Risks, and Management Commentary

• Guidance & Outlook: Management expects continued growth in CLAVE unit and dollar sales volume in the second half of 2002, primarily driven by Abbott and international distribution. However, they anticipate a slight decline in gross margin percentage for the second half due to a higher mix of labor-intensive custom products and continuing price declines.
• Capital Expenditures: The company expects capital expenditures for property and equipment to be between $14 million and $15 million in 2002. This includes investments in automated assembly, molding capacity, and a new Oracle enterprise software suite.
• Legal Contingencies: A significant risk involves ongoing litigation with B. Braun Medical Inc. regarding the CLAVE supply agreement and patent infringement. ICU Medical notified B. Braun that the agreement expires on December 31, 2002, and no extension is guaranteed. Failure to reach a new agreement could materially impact future revenues.
• Market Risks: The company faces competitive pressure leading to price erosion. Additionally, the market is shifting toward needleless, swabbable technology, which is expected to reduce sales of protected needle products.
• Unusual Items: The company switched independent auditors from Arthur Andersen LLP to Deloitte & Touche LLP in July 2002.

Investor Verification Checklist

• B. Braun Contract Status: Verify the outcome of negotiations with B. Braun for a post-2002 supply agreement, given the expiration of the current contract on December 31, 2002.
• Customer Concentration: Assess the risk of revenue volatility given that Abbott Laboratories accounted for 66% of YTD 2002 sales.
• Margin Sustainability: Monitor gross margins in the second half of 2002 to confirm if the anticipated slight decline materializes due to product mix changes.
• Capital Deployment: Track the execution of the $14-15 million capital expenditure plan, specifically the installation of the new Oracle software and expansion of Mexican assembly capacity.
• Legal Exposure: Review updates on the patent infringement lawsuit against B. Braun regarding the UltraSite product and the potential for monetary damages or injunctions.